ALXONasdaqPharmaceutical PreparationsFiscal year ends December 31
ALX ONCOLOGY HOLDINGS INC
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$1.14+0.08 (+7.55%)
Close on Oct 19, 2026
- Market cap
- $154.63M
- P/E (TTM)
- –
- Dividend yield
- –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
76.6%
106M of 138M shares
Institutional holders
94
37 new, 11 sold out
Net institutional buying
12M
In Q2 2026
Insider trades, 12 months
1 buys · 7 sales
Net bought $4.96M
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Redmile Group, LLC | 9,214,188 | 6.80% | 13G (passive) amendment | Mar 31, 2026 |
| HBM Healthcare Investments (Cayman) Ltd. | 8,590,692 | 6.50% | 13G (passive) amendment | Mar 31, 2026 |
| BlackRock, Inc. | 7,327,850 | 5.40% | 13G (passive) | Jun 30, 2026 |
| Tang Capital Partners, LP | 3,296,883 | 6.30% | 13G (passive) amendment | Dec 31, 2024 |
| Millennium Management LLC | 3,188,196 | 6.00% | 13G (passive) amendment | Oct 17, 2025 |
| Kevin Tang | 3,158,265 | 5.90% | 13G (passive) amendment | Mar 31, 2025 |
| Millennium Group Management LLC | 2,707,151 | 5.10% | 13G (passive) | Oct 2, 2025 |
| RA Capital Healthcare Fund, L.P. | 13,117,106 | 9.90% | 13G (passive) | Feb 2, 2026 |
| Goodman Corey S | 12,927,442 | 9.99% | 13D (active) amendment | Oct 14, 2026 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of ALXO | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Ra Capital Management, L.P. | 13,011,849 | 9.41% | $26.93M | – | 0.23% |
| venBio Partners LLC | 12,884,638 | 9.32% | $26.67M | – | 5.14% |
| BlackRock, Inc. | 7,399,530 | 5.35% | $15.32M | +6,951,731 | 0.00% |
| Redmile Group, LLC | 7,392,504 | 5.35% | $15.30M | −571,684 | 1.03% |
| Blackstone Inc. | 6,593,543 | 4.77% | $13.65M | +766,999 | 0.04% |
| Driehaus Capital Management LLC | 6,025,240 | 4.36% | $12.47M | +290,620 | 0.07% |
| Silverarc Capital Management, LLC | 5,744,757 | 4.15% | $11.89M | New | 1.24% |
| TCG Crossover Management, LLC | 5,655,487 | 4.09% | $11.71M | −7,356,362 | 0.28% |
| Vanguard Capital Management LLC | 4,973,436 | 3.60% | $10.30M | +793,700 | 0.00% |
| Vivo Capital, LLC | 3,184,713 | 2.30% | $6.59M | – | 0.60% |
| Marshall Wace, Llp | 3,071,496 | 2.22% | $6.36M | −685,720 | 0.01% |
| 5AM Venture Management, LLC | 3,057,325 | 2.21% | $6.33M | – | 2.20% |
| Almitas Capital LLC | 2,938,431 | 2.13% | $6.08M | −235,403 | 1.46% |
| Orbimed Advisors LLC | 2,866,256 | 2.07% | $5.93M | – | 0.11% |
| Geode Capital Management, LLC | 2,787,809 | 2.02% | $5.77M | +2,294,372 | 0.00% |
| Two Sigma Investments, LP | 2,178,176 | 1.58% | $4.51M | +590,343 | 0.00% |
| Millennium Management LLC | 1,543,594 | 1.12% | $3.20M | −444,965 | 0.00% |
| Nantahala Capital Management, LLC | 1,500,000 | 1.08% | $3.11M | New | 0.05% |
| State Street Corp | 1,498,905 | 1.08% | $3.10M | +1,323,077 | 0.00% |
| Acadian Asset Management LLC | 1,313,490 | 0.95% | $2.71K | +212,465 | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 94 | 106M | 76.6% | 37 / 29 | 10 / 11 | 27M | 16M |
| Q1 2026 | 69 | 94M | 68.2% | 25 / 18 | 12 / 12 | 70M | 3M |
| Q4 2025 | 57 | 29M | 21.1% | 8 / 19 | 15 / 10 | 3M | 4M |
| Q3 2025 | 61 | 30M | 22.0% | 8 / 10 | 31 / 8 | 7M | 5M |
| Q2 2025 | 61 | 29M | 21.0% | 10 / 9 | 32 / 34 | 2M | 8M |
| Q1 2025 | 85 | 35M | 25.2% | 8 / 26 | 30 / 9 | 2M | 8M |
| Q4 2024 | 87 | 41M | 29.7% | 21 / 32 | 20 / 26 | 8M | 13M |
| Q3 2024 | 92 | 46M | 32.9% | 18 / 40 | 21 / 36 | 12M | 12M |
| Q2 2024 | 112 | 49M | 35.2% | 31 / 37 | 27 / 23 | 9M | 7M |
| Q1 2024 | 106 | 47M | 33.6% | 23 / 29 | 30 / 10 | 3M | 3M |
| Q4 2023 | 93 | 46M | 33.4% | 32 / 33 | 16 / 14 | 16M | 3M |
| Q3 2023 | 76 | 33M | 24.1% | 12 / 23 | 22 / 10 | 1M | 2M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of ALXO | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 3,642,854 | 2.63% | $7.54M | 0.00% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 2,598,748 | 1.88% | $5.38M | 0.01% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund | 1,174,485 | 0.85% | $2.28M | 0.01% | Jul 31, 2026 |
| Vanguard Extended Market Index Fund | 1,164,899 | 0.84% | $2.41M | 0.00% | Jun 30, 2026 |
| iShares Russell 2000 Growth ETF | 1,013,254 | 0.73% | $2.10M | 0.01% | Jun 30, 2026 |
| JPMorgan U.S. Small Company Fund | 393,960 | 0.28% | $815.50K | 0.07% | Jun 30, 2026 |
| iShares Micro-Cap ETF | 361,777 | 0.26% | $748.88K | 0.05% | Jun 30, 2026 |
| Schwab Small-Cap Index Fund | 260,212 | 0.19% | $504.81K | 0.01% | Jul 31, 2026 |
| Ultra-Small Company Market Fund | 211,000 | 0.15% | $436.77K | 0.29% | Jun 30, 2026 |
| Master Small Cap Index Series | 201,688 | 0.15% | $417.49K | 0.01% | Jun 30, 2026 |
| Fidelity Extended Market Index Fund | 187,907 | 0.14% | $357.02K | 0.00% | May 31, 2026 |
| U.S. Small Cap Equity Fund | 146,676 | 0.11% | $284.55K | 0.03% | Jul 31, 2026 |
| Nuveen Small Cap Blend Index Fund | 143,645 | 0.10% | $278.67K | 0.01% | Jul 31, 2026 |
| EQ/2000 Managed Volatility Portfolio | 115,694 | 0.08% | $239.49K | 0.01% | Jun 30, 2026 |
| Fidelity Small Cap Growth Index Fund | 100,498 | 0.07% | $208.03K | 0.01% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Jason Lettmann | CHIEF EXECUTIVE OFFICER, Director | 2,393,474 | 1.73% | Aug 18, 2026 |
| Shelly Pinto | SVP, FINANCE AND CAO | 87,828 | 0.06% | Aug 18, 2026 |
| Barbara Klencke | Chief Medical Officer | 120,000 | 0.09% | Apr 17, 2026 |
| Jeff E. Knight | Chief Dev & Operating Officer | – | – | Apr 17, 2026 |
| Harish Shantharam | Chief Financial Officer | 75,000 | 0.05% | Jan 28, 2026 |
| Jaume Pons | PRESIDENT & CSO | 579,388 | 0.42% | Feb 21, 2025 |
| Corey S. Goodman | Director, 10% owner | 8,453,038 | 6.11% | Feb 4, 2026 |
| Rekha Hemrajani | Director | 33,000 | 0.02% | Jan 21, 2026 |
| J. Scott Garland | Director | – | – | Jan 21, 2026 |
| Alan B. Sandler | Director | – | – | Jan 21, 2026 |
| Daniel J. Curran | Director | – | – | Jan 21, 2026 |
| Chris H. Takimoto | Director | – | – | Jan 21, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Shelly Pinto SVP, FINANCE AND CAO | Aug 17, 2026 | Sale | −573 | $1.93 | $1.11K | 87,828 |
| Jason Lettmann CHIEF EXECUTIVE OFFICER, Director | Aug 17, 2026 | Sale | −2,230 | $1.93 | $4.30K | 294,379 |
| Shelly Pinto SVP, FINANCE AND CAO | Jul 1, 2026 | Sale | −1,404 | $2.04 | $2.86K | 88,401 |
| Shelly Pinto SVP, FINANCE AND CAO | Mar 19, 2026 | Sale | −903 | $2.17 | $1.96K | 86,805 |
| Jason Lettmann CHIEF EXECUTIVE OFFICER, Director | Mar 19, 2026 | Sale | −12,311 | $2.17 | $26.71K | 293,609 |
| Shelly Pinto SVP, FINANCE AND CAO | Feb 18, 2026 | Sale | −565 | $2.27 | $1.28K | 87,708 |
| Jason Lettmann CHIEF EXECUTIVE OFFICER, Director | Feb 17, 2026 | Tax withholding | −2,201 | $2.27 | $5.00K | 305,920 |
| Corey S. Goodman Director, 10% owner | Feb 2, 2026 | Buy | +3,184,713 | $1.57 | $5.00M | 8,453,038 |
| Shelly Pinto SVP, FINANCE AND CAO | Jan 6, 2026 | Sale | −3,925 | $1.11 | $4.36K | 88,273 |
| Jason Lettmann CHIEF EXECUTIVE OFFICER, Director | Sep 17, 2025 | Buy | +71,163 | $1.08 | $76.86K | 305,121 |
| Jason Lettmann CHIEF EXECUTIVE OFFICER, Director | Sep 16, 2025 | Buy | +21,070 | $1.07 | $22.54K | 233,958 |
| Harish Shantharam Chief Financial Officer | Aug 18, 2025 | Buy | +75,000 | $0.78 | $58.50K | 75,000 |
| Jason Lettmann CHIEF EXECUTIVE OFFICER, Director | Aug 15, 2025 | Sale | −2,382 | $0.64 | $1.52K | 212,888 |
| Shelly Pinto SVP, FINANCE AND CAO | Aug 15, 2025 | Sale | −611 | $0.64 | $391 | 89,198 |
| Shelly Pinto SVP, FINANCE AND CAO | Jul 7, 2025 | Sale | −2,011 | $0.45 | $905 | 86,809 |
| Shelly Pinto SVP, FINANCE AND CAO | Jun 30, 2025 | Sale | −1,532 | $0.43 | $659 | 88,820 |
| Jason Lettmann CHIEF EXECUTIVE OFFICER, Director | Mar 14, 2025 | Award | +42,000 | – | – | 212,270 |
| Shelly Pinto SVP, FINANCE AND CAO | Mar 14, 2025 | Award | +3,000 | – | – | 90,352 |
| Shelly Pinto SVP, FINANCE AND CAO | Feb 19, 2025 | Sale | −550 | $1.15 | $633 | 87,352 |
| Jaume Pons PRESIDENT & CSO | Feb 19, 2025 | Sale | −1,326 | $1.15 | $1.52K | 579,388 |
| Jason Lettmann CHIEF EXECUTIVE OFFICER, Director | Feb 19, 2025 | Sale | −2,159 | $1.15 | $2.48K | 170,270 |
| Shelly Pinto Interim CFO | Jan 6, 2025 | Sale | −2,221 | $1.80 | $4.00K | 87,902 |
| Shelly Pinto Interim CFO | Dec 30, 2024 | Sale | −1,426 | $1.58 | $2.25K | 90,123 |
| Jaume Pons PRESIDENT & CSO | Dec 30, 2024 | Sale | −10,796 | $1.58 | $17.06K | 580,714 |
| Rekha Hemrajani Director | Dec 2, 2024 | Buy | +30,000 | $1.55 | $46.50K | 33,000 |
| Jaume Pons PRESIDENT & CSO | Aug 14, 2024 | Sale | −1,937 | $2.58 | $5.00K | 591,510 |
| Shelly Pinto SVP, FINANCE AND CAO | Aug 14, 2024 | Sale | −564 | $2.58 | $1.46K | 91,549 |
| Sophia Randolph CHIEF MEDICAL OFFICER | Aug 14, 2024 | Sale | −1,365 | $2.58 | $3.52K | 325,711 |
| Jason Lettmann CHIEF EXECUTIVE OFFICER, Director | Aug 14, 2024 | Tax withholding | −2,191 | $2.58 | $5.65K | 169,429 |
| Peter S. Garcia CHIEF FINANCIAL OFFICER | Aug 14, 2024 | Tax withholding | −761 | $2.58 | $1.96K | 121,516 |
| Jaume Pons PRESIDENT & CSO, Director | Jul 11, 2024 | Option exercise | +20,000 | $0.99 | $19.80K | 613,447 |
| Jaume Pons PRESIDENT & CSO, Director | Jul 11, 2024 | Sale(10b5-1 plan) | −20,000 | $7.90 | $158.00K | 593,447 |
| Shelly Pinto SVP, FINANCE AND CAO | Jul 5, 2024 | Sale | −1,823 | $5.50 | $10.03K | 92,113 |
| Shelly Pinto SVP, FINANCE AND CAO | Jul 1, 2024 | Sale | −1,373 | $5.82 | $7.99K | 93,936 |
| Jaume Pons PRESIDENT & CSO, Director | Jul 1, 2024 | Sale | −10,758 | $5.82 | $62.61K | 593,447 |
| Sophia Randolph CHIEF MEDICAL OFFICER, Director | Jul 1, 2024 | Sale | −3,273 | $5.82 | $19.05K | 327,076 |
| Peter S. Garcia CHIEF FINANCIAL OFFICER | Jun 28, 2024 | Tax withholding | −1,789 | $6.03 | $10.79K | 122,277 |
| Peter S. Garcia CHIEF FINANCIAL OFFICER | Jun 13, 2024 | Buy | +12,000 | $8.53 | $102.36K | 122,348 |
| Peter S. Garcia CHIEF FINANCIAL OFFICER | Jun 13, 2024 | Buy | +12,000 | $8.53 | $102.36K | 122,348 |
| Jaume Pons PRESIDENT & CSO, Director | Jun 4, 2024 | Sale(10b5-1 plan) | −20,000 | $8.43 | $168.60K | 604,205 |
| Jaume Pons PRESIDENT & CSO, Director | Jun 4, 2024 | Option exercise | +20,000 | $0.99 | $19.80K | 624,205 |
| Sophia Randolph CHIEF MEDICAL OFFICER, Director | May 13, 2024 | Sale(10b5-1 plan) | −1,797 | $16.67 | $29.96K | 330,349 |
| Sophia Randolph CHIEF MEDICAL OFFICER, Director | May 13, 2024 | Sale(10b5-1 plan) | −10,203 | $15.82 | $161.41K | 332,146 |
| Jaume Pons PRESIDENT & CSO, Director | May 6, 2024 | Sale(10b5-1 plan) | −20,000 | $15.92 | $318.40K | 604,205 |
| Jaume Pons PRESIDENT & CSO, Director | May 6, 2024 | Option exercise | +20,000 | $0.99 | $19.80K | 624,205 |
| Jaume Pons PRESIDENT & CSO, Director | Apr 16, 2024 | Sale(10b5-1 plan) | −50,000 | $14.20 | $710.00K | 604,205 |
| Jaume Pons PRESIDENT & CSO, Director | Apr 16, 2024 | Option exercise | +25,846 | $0.99 | $25.59K | 654,205 |
| Jaume Pons PRESIDENT & CSO, Director | Apr 4, 2024 | Sale(10b5-1 plan) | −20,000 | $11.15 | $223.00K | 628,359 |
| Jason Lettmann CHIEF EXECUTIVE OFFICER, Director | Mar 14, 2024 | Buy | +4,400 | $11.31 | $49.76K | 171,620 |
| Sophia Randolph CHIEF MEDICAL OFFICER, Director | Feb 14, 2024 | Award | +30,000 | – | – | 342,349 |
| Jaume Pons PRESIDENT & CSO, Director | Feb 14, 2024 | Award | +30,000 | – | – | 648,359 |
| Shelly Pinto SVP, FINANCE AND CAO | Feb 14, 2024 | Award | +15,000 | – | – | 93,591 |
| Jason Lettmann CHIEF EXECUTIVE OFFICER, Director | Feb 14, 2024 | Award | +60,000 | – | – | 167,220 |
| Peter S. Garcia CHIEF FINANCIAL OFFICER | Feb 14, 2024 | Award | +25,000 | – | – | 110,348 |
| Shelly Pinto SVP, Finance and CAO | Jan 4, 2024 | Sale | −2,717 | $13.60 | $36.95K | 78,591 |
| Peter S. Garcia Chief Financial Officer | Dec 29, 2023 | Sale | −1,893 | $15.04 | $28.47K | 85,348 |
| Shelly Pinto SVP, Finance and CAO | Dec 29, 2023 | Sale | −1,631 | $15.04 | $24.53K | 81,308 |
| Sophia Randolph Chief Medical Officer, Director | Dec 29, 2023 | Sale | −3,128 | $15.04 | $47.05K | 312,349 |
| Jaume Pons President & CSO, Director | Dec 29, 2023 | Sale | −7,179 | $15.04 | $107.97K | 618,359 |
| Shelly Pinto SVP, Finance and CAO | Jul 25, 2023 | Award | +26,000 | – | – | 81,713 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Jaume Pons Officer | Jul 11, 2024 | 20,000 | $135.20K | Jul 11, 2024 | Options Grant |
| Jaume Pons Officer | Jun 4, 2024 | 20,000 | $179.20K | Jun 4, 2024 | Options Grant |
| Sophia Randolph Officer | May 13, 2024 | 78,000 | $1.26M | May 13, 2024 | Restricted stock |
| Jaume Pons Officer | May 6, 2024 | 20,000 | $307.20K | May 6, 2024 | Options Grant |
| Jaume Pons Officer | Apr 16, 2024 | 50,000 | $644.50K | Apr 16, 2024 | Options Grant |
| Jaume Pons Officer | Apr 4, 2024 | 20,000 | $216.00K | Apr 4, 2024 | Restricted Stock from Option Exercise |